August 09, 2024

REP. CORREA STATEMENT ON FDA’S MDMA-AT DECISION

SANTA ANA, Calif. — Today, following the Food and Drug Administration’s announcement to reject the use of MDMA-assisted therapies trialed as a treatment for post-traumatic stress disorder, Representative Lou Correa (CA-46), co-chair of the Congressional Psychedelics Advancing Therapies (PATH) Caucus, released the following statement:

“Today, the FDA got it wrong in a big way. MDMA-assisted therapy has been proven time and time again to be safe and effective–up to 90% effective–for treating veterans with PTSD. In fact, many veterans have said that they wouldn’t be here today if it weren’t for MDMA-assisted therapy. Yet the FDA has again chosen to ignore the science and listen to stigma and bias. This FDA decision will cost many veterans their lives,” Correa said. “This decision means that veterans will have to continue to go abroad to receive treatment because the country they fought for refuses to follow the science. It also means that we’ll continue to lose over 17 veterans a day to suicide. Our veterans need this treatment now—and I will continue to be a strong advocate for them. Our nation’s veterans had our back, and now we must have theirs.”

###